Medgenics: ASN 2015 (Medgenics) - Nov 21, 2015 - “All patients had good initial response in both EPO and reticulocytes/Hb”; “Thus far, 9/13 patients had 5 or more months of TARGTEPO secretion with stable Hb response. One patient is over 16 months with stable EPO secretion and Hb response and several patients are still in active follow up. PD and HD patients shows comparable results”; “TARGT platform proved its advantage of dose control in patients and recapitulated the findings in animal models, one TARGT excision in patient 401 d/t Hb above 13 g/dL resulted in reduction in both EPO and Hb levels”
P1/2 data • Biosimilar
|